Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 2
2022 2
2023 4
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Genetic architecture of plasma Alzheimer disease biomarkers.
Bradley J, Gorijala P, Schindler SE, Sung YJ, Ances B; Alzheimer’s Disease Neuroimaging Initiative, the Human Connectome Project; Fernandez MV, Cruchaga C. Bradley J, et al. Hum Mol Genet. 2023 Jul 20;32(15):2532-2543. doi: 10.1093/hmg/ddad087. Hum Mol Genet. 2023. PMID: 37208024 Free PMC article.
Timing of Biomarker Changes in Sporadic Alzheimer's Disease in Estimated Years from Symptom Onset.
Li Y, Yen D, Hendrix RD, Gordon BA, Dlamini S, Barthélemy NR, Aschenbrenner AJ, Henson RL, Herries EM, Volluz K, Kirmess K, Eastwood S, Meyer M, Heller M, Jarrett L, McDade E, Holtzman DM, Benzinger TLS, Morris JC, Bateman RJ, Xiong C, Schindler SE. Li Y, et al. Ann Neurol. 2024 May;95(5):951-965. doi: 10.1002/ana.26891. Epub 2024 Feb 24. Ann Neurol. 2024. PMID: 38400792
The PrecivityAD™ test: Accurate and reliable LC-MS/MS assays for quantifying plasma amyloid beta 40 and 42 and apolipoprotein E proteotype for the assessment of brain amyloidosis.
Kirmess KM, Meyer MR, Holubasch MS, Knapik SS, Hu Y, Jackson EN, Harpstrite SE, Verghese PB, West T, Fogelman I, Braunstein JB, Yarasheski KE, Contois JH. Kirmess KM, et al. Clin Chim Acta. 2021 Aug;519:267-275. doi: 10.1016/j.cca.2021.05.011. Epub 2021 May 17. Clin Chim Acta. 2021. PMID: 34015303 Free PMC article.
Assessment of a Plasma Amyloid Probability Score to Estimate Amyloid Positron Emission Tomography Findings Among Adults With Cognitive Impairment.
Hu Y, Kirmess KM, Meyer MR, Rabinovici GD, Gatsonis C, Siegel BA, Whitmer RA, Apgar C, Hanna L, Kanekiyo M, Kaplow J, Koyama A, Verbel D, Holubasch MS, Knapik SS, Connor J, Contois JH, Jackson EN, Harpstrite SE, Bateman RJ, Holtzman DM, Verghese PB, Fogelman I, Braunstein JB, Yarasheski KE, West T. Hu Y, et al. JAMA Netw Open. 2022 Apr 1;5(4):e228392. doi: 10.1001/jamanetworkopen.2022.8392. JAMA Netw Open. 2022. PMID: 35446396 Free PMC article.
Plasma Aβ42/Aβ40 and phospho-tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer's disease.
Rissman RA, Langford O, Raman R, Donohue MC, Abdel-Latif S, Meyer MR, Wente-Roth T, Kirmess KM, Ngolab J, Winston CN, Jimenez-Maggiora G, Rafii MS, Sachdev P, West T, Yarasheski KE, Braunstein JB, Irizarry M, Johnson KA, Aisen PS, Sperling RA; AHEAD 3-45 Study team. Rissman RA, et al. Alzheimers Dement. 2024 Feb;20(2):1214-1224. doi: 10.1002/alz.13542. Epub 2023 Nov 6. Alzheimers Dement. 2024. PMID: 37932961 Free PMC article.
Clinical validation of the PrecivityAD2 blood test: A mass spectrometry-based test with algorithm combining %p-tau217 and Aβ42/40 ratio to identify presence of brain amyloid.
Meyer MR, Kirmess KM, Eastwood S, Wente-Roth TL, Irvin F, Holubasch MS, Venkatesh V, Fogelman I, Monane M, Hanna L, Rabinovici GD, Siegel BA, Whitmer RA, Apgar C, Bateman RJ, Holtzman DM, Irizarry M, Verbel D, Sachdev P, Ito S, Contois J, Yarasheski KE, Braunstein JB, Verghese PB, West T. Meyer MR, et al. Alzheimers Dement. 2024 May;20(5):3179-3192. doi: 10.1002/alz.13764. Epub 2024 Mar 16. Alzheimers Dement. 2024. PMID: 38491912 Free PMC article.
A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis.
West T, Kirmess KM, Meyer MR, Holubasch MS, Knapik SS, Hu Y, Contois JH, Jackson EN, Harpstrite SE, Bateman RJ, Holtzman DM, Verghese PB, Fogelman I, Braunstein JB, Yarasheski KE. West T, et al. Mol Neurodegener. 2021 May 1;16(1):30. doi: 10.1186/s13024-021-00451-6. Mol Neurodegener. 2021. PMID: 33933117 Free PMC article.
The Association of Alzheimer's Disease-related Blood-based Biomarkers with Cognitive Screening Test Performance in the Congolese Population in Kinshasa.
Schwinne M, Alonso A, Roberts BR, Hickle S, Verberk IM, Epenge E, Gikelekele G, Tsengele N, Kavugho I, Mampunza S, Yarasheski KE, Teunissen CE, Stringer A, Levey A, Ikanga J. Schwinne M, et al. medRxiv [Preprint]. 2023 Oct 31:2023.08.28.23294740. doi: 10.1101/2023.08.28.23294740. medRxiv. 2023. PMID: 37693503 Free PMC article. Updated. Preprint.
11 results